Related Experiment Video

Updated: Mar 13, 2026

Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation
10:24

Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation

Published on: September 19, 2019

6.8K

Evolution from genetics to phenotype: reinterpretation of NSCLC plasticity, heterogeneity, and drug resistance

Yingjiao Xue1,2,3,4, Shenda Hou1,2,3,4, Hongbin Ji1,2,3,5,4

  • 1Key Laboratory of Systems Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, 200031, China.

Protein & Cell
|October 21, 2016
PubMed

Insights

Lung cancer plasticity and heterogeneity drive drug resistance, impacting patient outcomes. Understanding these dynamics offers new therapeutic strategies for improved lung cancer treatment.

Area of Science:

  • Oncology
  • Cancer Biology
  • Pharmacology

Background:

  • Lung cancer remains a leading cause of cancer mortality globally.
  • Targeted therapies improve outcomes but face challenges due to acquired drug resistance.
  • Mechanisms of resistance include genetic alterations, bypass signaling, and phenotypic transitions.

Purpose of the Study:

  • To review the concepts of lung cancer plasticity and heterogeneity.
  • To explore the correlation between these dynamic properties and the development of drug resistance.
  • To discuss the potential of targeting plasticity and heterogeneity for improved cancer prognosis and treatment.

Main Methods:

  • Literature review of studies on lung cancer biology and drug resistance.
  • Synthesis of current understanding of cancer plasticity and heterogeneity.
  • Analysis of mechanisms contributing to therapeutic resistance in lung cancer.

Main Results:

  • Lung cancer exhibits significant plasticity and heterogeneity, contributing to treatment failure.
  • Dynamic cellular regulations, both intrinsic and extrinsic, enable tumor cell survival under therapeutic pressure.
  • These properties are crucial in the development and maintenance of drug resistance.

Conclusions:

  • Lung cancer plasticity and heterogeneity are key drivers of therapeutic resistance.
  • Manipulating these characteristics presents potential opportunities for novel treatment strategies.
  • Addressing plasticity and heterogeneity is essential for overcoming drug resistance and improving lung cancer patient survival.
Keywords:
drug resistanceheterogeneitylung cancerphenotypic transitionplasticity

More Related Videos

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.7K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.7K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
61
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
83
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.3K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

4.2K
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
70